GATA3 and signet ring cell carcinoma: By comparing the results of our RT-qPCR and immunohistochemical analyses of GATA3 expression with the clinicopathological characteristics of the patients, GATA3 expression was found to be significantly reduced in patients with large tumors (P = 0.017), signet ring cell carcinoma/mucinous carcinoma (P = 0.005), and tumors with lymphatic/venous invasion (P = 0.040).